Crossbow Therapeutics

Focus: Crossbow Therapeutics is a newly-founded (2024) Cambridge-based biotechnology company focused on antibody therapies for oncology indications. The company is publicly listed but remains in early clinical stages with minimal commercial footprint.

Oncology Unknown

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Crossbow Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Crossbow Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CBX-250

High-risk Myelodysplastic Syndrome

PHASE_1

Clinical Trials (1)

NCT06994676A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Phase 1

Help build intelligence for Crossbow Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a publicly-traded biotech with fresh capital access and strategic clarity in antibody drug development
Focus on high-impact oncology (myelodysplastic syndrome) represents meaningful therapeutic area with unmet need
Early-stage pipeline offers potential for broad-based career growth before organizational scaling becomes rigid

Watch Out For

Only 1 active Phase 1 program (CBX-250) represents extremely thin clinical pipeline with no near-term catalysts or derisking events
Minimal hiring activity (1 active job) and null employee count suggest the company is either undercapitalized, pre-scaling, or facing organizational challenges that limit near-term career advancement

Generated by Claude from Crossbow Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.